Abstract
Background: Osteoporosis affects 200 million women worldwide, and fractures resulting from bone fragility are a major complication. Bisphosphonates slow down bone resorption by osteoclasts and have been shown to lower the risk of hip fractures among patients with osteoporosis in clinical trial settings. Most clinical guidelines recommend pharmacological treatment for postmenopausal women with an existing fracture or bone density T-score of -2.5 or lower. These guidelines were based on randomized controlled trials that typically lasted 3–4 years, although some of these studies have been extended for up to 10 years. We undertook this study to examine the association between adherence with bisphosphonate therapy and long-term risk of hip fracture, using up to 14 years of retrospective observation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
